Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Genomic Strategy to Assess Mutation Clearance in AML
NCT02756962Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2016
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cytarabine in acute myeloid leukemia (AML) (2 cohorts), sponsored by Washington University School of Medicine. Primary endpoint: Relapse-Free Survival at 5 years. Started Jul 2016; status: active, not recruiting.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02756962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02756962.